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The objective of the present study was to evaluate factors of the plasma kallikrein system in patients with acute nonlymphoblastic
leukemia (ANLL), and compare the results to a normal control group. A prospective study was performed in the Tertiary Health Care
Institution, Hemocentro, Campinas State University, Campinas, São Paulo, Brazil. Thirty-five patients, diagnosed as ANLL between
1988 and 1991, were considered for participation. Eleven patients were not elegible, according to the exclusion criteria: infection/
septicemia, previous treatment or blood transfusion. The study was performed with 24 ANLL patients, average age 34 years (16-69
years), 14 men and 10 women. Nineteen healthy volunteers, workers from the Hematology Center, average age 32 years (21-59
years), 11 men and 8 women, were .the control group. Plasmatic prekallikrein, C1-inhibitor, alpha 2-macroglobulin, activated partial
thromboplastin time, prothrombin time, factor XII, factor XI, factor V and prealbumin were measured. Plasmatic prekallikrein (p=O.02)
and prealbumin (p=O.03)were significantly decreased, and prothrombin time increased (p=O.003) in the patient group when compared
to the control. Significantcorrelation (r=O.49,criticai value=O.43,p<O.05)between prekállikrein and prealbumin, and between prothrombin
time and factor V (r=O.54, criticai value=O.44, p<O.05) was demonstrated in the patient group. No correlation was found between
parameters analysed and circulant blast count or leukemia subgroups. Statistical analysis was performed by theWilcoxon tes1.Correlation
between the parameters was also verified. These results suggest activation of the contact system or impaired Iiver synthesis in
patients with ANLL, and could contribute to disease complications.
UNITERMS: Plasmatic prekallikrein. Contact phase. Nonlymphoblastic leukemia.
INTRODUCTION
FactorXII, plasmatic prekallikrein (PK) and HMW-kininogen play an essential role in the initiation ofimp9rtant biological reactions, including intrinsic
coagulation pathway. Recently,- tecidual kallikrein and
prekallikrein-kininogen complexes have been identified in
neutrophils and myeloid precursors.I Studies "in vitro"
demonstrate that granulocyiic elastase is capable of cleaving
HMW-kininogen, PK and factors XII and XI. In addition,
it can cleave Cl-inhibitor to an inactive form.I
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Disturbances of hemostasis are still a major problem
in patients with acute leukemia, and activation of the
contact phase or proteolysis of contact system components,
if present, could contribute to these alterations.
Although a relationship exists between leukocytes
and the kallikrein-kinin system, there are few clinicaI
studies on leukemia patients.
Chiba et aI (1979) studied 14 acute myelocytic
leukemia patients. Before and during the treatment they
found decreased plasmatic PK and normal CI-INH.
Buzerak et aI (1982) studied 39 patients with acute
leukemia and described increased kallikrein-kinin system
activation in patients with a higher blast count.
. . This study was undertaken to evaluate some contact
system parameters in 24 patients with ANLL at diagnosis,
compared to a control group, and to verify correlation
between possible alterations and bla~t count, some
coagulation parameters and prealbumin.
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PATIENTS AND METHODS
Blood samples were collected by clean venipuncture,
in plastic tubes containing sodium citrate 3,8%, in a 9: 1
proportion. Following its centrifugation, the obtained
plasma was kept at -80DC until its use.
A prospective study, including all new cases diagnosed
as ANLL in the Hemocentro at Unicamp between 1988 to
1991, was developed. Thirty-five cases of ANLL were
considered for participation in this study. Eleven patients
were not elegible, according to the exclusion cri teria:
infection/septicemia, previous treatment or blood
transfusion. Infection/septicemia was ruled out in the
absence of fever, negative blood and urine culture, normal
thorax X-ray and stable blood pressure. Finally, blood was
analysed from 24 ANLL patients, average age 34 years (16-
69 years), 14 men and 10 women. Diagnosis of renewed
ANLL was based on blood count, bone marrow biopsy,
cytology and cytochemistry. They were classified according
to the FAB-system4 (six Ml, nine M2, one M3, two M4,
two M5, two M6 and two M7 cases). ClinicaI bleeding was
present in 5 patients (21 % of cases) and characterized by
epistaxis (cases 4 and 13), ecchymosis (cases 7 and 16) and
hematuria (case 23). ClinicaI thrombosis was not presente
Nineteen healthy volunteers, workers from the Hemocentro
at Unicamp, average age 32 years (21-59 years), 11 men
and 8 women, were the control group.
Plasmatic PK was measured after dextran sulphate
activation, using an amidolytic assay~ with
Ac-Phe-Arg-pNA chromogenic substrate.~ "Kallikrein-
Iike" activity was evaIuated in the same way as the
prekallikrein assay, substituting dextran sulphate as buffer.
Cl-inhibitor (CI-INH), alpha 2-macrogIobuIin (A2)
and preaIbumin (PA) were measured by rocket
immunoeIectrophoresis.7 Acti vated partiaI thromboplastin
time (APTT) was measured with kaolin and rabbit brain
cephalin.8 Prothrombin time (PT) was obtained with rabbit
brain thromboplastin.9 The APTT and PT results were
expressed as' a ratio between coagulation time of patient
plasma and a pool of 20 normal plasmas. Normal and
prolonged APTT and PT reference plasmas were run daily
as a laboratory quality controI. Factor XI and factor XII
were measured by APTT corrrection time, using deficient
plasma in factor XI and XII (Stago diagnosis)
respectively.lO Factor V was .measured by a described
procedure.11
Platelet count was determined automatically (CeII
dyn 1600, Unipath, California, USA).
Statistical analysis was carried out using the
Wilcoxon teste Patients and controIs were compared to all
parameters studied. Patients were .also separated according
to leukemia subtypes, into group 1 (M1- 6 cases), group 2
(M2- 9 cases) and group 3 (M3 to M7- 8 cases). This last
group was made up from 4 subgroups, to achieve a great
number of patients, making statistical analysis possible.
Correlation between various parameters was performed:
blast count or leucocyte count and PK; CI-INH or A2; PA
and PK, PT or factor V; and PK and PT or factor V. The
difference at p < 0.05 was considered significant.
RESULTS
Table 1 summarizes peripheral blood count found in
ANLL patients.
labia 1
Blood count of ANLL patients
hemoglobin leucocytes blasts platelets
g/dl /mm3 /mm3 /mm3
1.M1 8,1 3000 1500 62000
L 2.M1 10,0 3400 1600 55000
E 3.M1 7,5 1100 500 47000
U 4.M1 5,1 5100 1800 20000
K 5.M1 9,3 130000 111000 84000
E 6.M1 7,3 26000 18000 35000
M 7.M2 7,5 1500 900 15000
I 8.M2 7,6 2500 1900 21000
A 9.M2 8,8 6000 4000 90000
10.M2 7,5 11400 8700 102000
11.M2. 6,8 2100 1100 176000
S 12.M2 4,3 145000 110000 55000
U 13.M2 8,8 3500 1200 12000
B 14.M2 8,2 188000 165000 75000
G 15.M2 11,5 50000 38000 68000
R 16.M3 8,4 3500 2000 2000
O 17.M4 9,4 1900 1100 25000
U 18.M4 10,7 22200 12000 59000
P 19.M5 8,0 20000 15000 10000
S 20.M5 7,0 30000 18000 42000
21.M6 10,0 1200 800 40000
22.M6 6,1 157000 137000 35000
23.M7 5,0 73000 56000 36000
24.M7 6,3 4000 1800 10000
average 7.8 3P~66 29070 49000
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The results (tables 2 and 3) demonstrated that APTT, DISCUSSION
CI-INH, A2, factor XI, factor XII and factor V were not
different between patients and the controI group. Kallikrein- Disturbances ofhemostasis are still a frequent problem
Iike activity was not increased in patients. PK was decreased in patients with acute Ieukemia. Prekallikrein or factor XII
(p=0.02) and PT increased (p=0.003) in ANLL patients deficiency are associated with an in vitro coagulopathy
when compared to the controI. PA was significantly Iower (prolonged APTT), in the absence of clinicaI bleeding.
(p=O.03) in the patient group than in the controI one. When However, if activation of the contact system or proteolysis
patients were separated into subgroups according to FAB- of the components of this system is present in leukemia,
classification, no difference was verified in any variable intrinsic blood coagulation pathway could be compromised,
measured. There was no correlation between circulant blast contributing to the coagulopathy seen in these patients.
count or Ieucocyte count and PK, A2 or CI-INH. A positive The objective of this study was to evaluate some
correlation between PK and PA (~0.49, criticaI value = components of the contact system in 24 ANLL patients. Patients
0.43, p<0.05), and between PT and factor V (r=0.54, criticaI were studied at diagnosis, without chemotherapy or infection,
value=0.44, p<0.05), was observed. to avoid conditions which could, per se, alter the contact system.
Table 2
Parameters of the contact system, coagulation and PA in ANLL
(R) Ratio of time of coagulation in seconds of patient to a pool of normal plasma.
APTT PK C1 A2 XI XII PA PT FV
(R) (U/ml) (%) (%) (%) (%) (%) R (%)
1.M1 1.35 0.26 78 82 120 69 47 1.2 70
L 2.M1 1.18 0.61 86 107 120 160 68 1.1 70
E 3.M1 1.02 0.17 89 93 63 77 42 1.3 100
U 4.M1 0.94 0.31 71 106 73 119 50 1.4 120
K 5.M1 0.96 0.23 86 81 121 69 1.0 80
E 6.M1 1.00 0.41 106 108 99 133 81 1.0
M 7.M2 0.95 0.40 100 100 112 160 100 1.1 72
I 8.M2 1.02 0.41 94 108 103 153 56 1.0 62
A 9.M2 ' 0~90 0.41 79 96 101 86 50 1.4 120
10.M2 1.02 0.62 92 75 108 66 50 1.2 105
11.M2 1.03 0.35 92 67 103 153 40 1.1 54
5 12.M2 0.95 0.43 87 129 74 109 40 1.4 56
U 13.M2 0.88 0.76 87 92 175 118 100 1.5 100
B 14.M2 0.77 0.36 95 75 48 128 70 1.2 92
G 15.M2 1.22 0.12 90 167 65 44 1.2 56
R 16.M3 1.20 0.57 100 142 40 34 73 1.2 110
O 17.M4 1.14 0.29 70 150 58 71 46 1.5 35
U 18.M4 1.02 0.60 75 87 119 109 200 1.2 140
P 19.M5 1.35 0.19 90 118 66 66 80 120
5 20.M5 1.04 0.20 90 157 100 190 43 1.3 60
21.M6 0.76- 0.62 81 108 139 171 87 1.2 120
22.M6 1.17 0.46 100 154 58 94 1.3 82
23.M7 1.52 0.53 93 86 160 120 67 1.1 105
24.M7 1.24 0.67 70 175 175 135 100 1.2 100
average 1.07 0.41 87 110 100 109 70 1.22 87
5D 0.18 0.17 9 31 37 42 36 0.15 27
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labia 3
Parameters of the contact system and coagulation
in ANLL and control group
(R) Ratio of coagulation time in seconds of patient to
a pool of normal plasmas.
Patient Control
APTT R 1.0 1.06
PK (U/ml) 0.41 0.52*
C1 (%) 87 93
A2 (%) 110 109
XI (%) 100 101
XII (%) 109 100
PT R 1.22 1.10**
V (%) 92 87
PA (%) 70 111***
* p=O.02
**p=O.OO3
***p=O.03
Bleeding was present in 21% of cases, a little less
than that described by others, and thrombocytopenia was
probably the major responsible factor. The exclusion of
patients with infection/septicemia, a condition that
increases the risk of bleeding in patients with
thrombocytopenia, could explain the lower incidence of
hemorrhagia in our patients.
We have demonstrated that ANLL patients have low
biologic PK activity. This fact could suggest an activation
of the contact phase, as described in previous reports. 2,3
Otherwise, the lack of reduction of the main PK
inhibitor, could disprove that the kallikrein-kinin system
has been activated in leukemia patients. 5tudies
demonstrated increased synthesis of C1-INH in
inflammatory processes, mediated by interleucin-6,
inferring that it could be an acute phase protein.12-13 The
normal leveI of C 1-INH in our patients does not role out
increased turnover, since synthesis could be increased,
associated with simultaneous consumption, by kallikrein-
kinin system activation. C1-INH antigen frequently is not.
reduced even after consumption of the inhibitor by an
active enzyme; the antigen may even appear increased in
Laurell assay, due to faster electrophoretic mobility of the
enzyme-inhibitor complexo Indeed, the immunolog'ic
method employed for C1-INH measurement can reveal
leveIs of inactive inhibitors.6,14-15
Kallikrein is present in leucocytes and myeloid
precursors. 50, in leukemia, a disease with an increased
number of these cells, we could expected a correlation
between blast cell count and PK, C 1or A2 leveIs. However,
our results did not confirm this hypothesis.
Kallikrein-like activity was not increased in our
patients, suggesting there was no spontaneous proteolysis
triggered by enzymes liberated from blasts cells.
PK is synthetized in liver, and it can be a reliable
index of liver function.'6 Impaired liver function could
contribute to the decreased PK leveI in our patients. The
finding of decreased PA, a sensitive parameter of liver
synthesis, and a significative correlation between PK and
PA in our ANLL patients, corroborate this hipothesis.
However, we have to take into account that prealbumin
can be decreased in clinicaI situations without liver
synthesis insufficiency, in which a modulation of protein
synthesis occurs, with an increase in acute phase proteins
and reduction in others. The great majority of these
~lterations are mediated by cytokines that act on
hepatocytes.17 The evaluation of other proteins that are
involved in acute phase response, like fibrinogen, reactive
. protein C and alpha 1-antitripsin, would be an important
aid in the analysis of our results.
Previous studies described coagulation
abnormalities in myelocytic Ieukemia, particularly in the .
subtype M3. Blast cells are rich in procoagulants which
can trigger blood coaguIation by direct factor X
activation, or by tissue factor-like activity. In some
patients the activation of blood coagulation can determine
an increase of APTT, PT and thrombin time. Activation
markers ofblood coagulation, like thrombin-antithrombin
complexes, fibrinogen degradation products and D-
dimmers, are of interest in confirming this activation or
not. In our patients, PT and PTTA were measured and
PT was the only parameter altered.
PT increases by reduction of factor 11, VII, X or
fibrinogen. 50, impaired liver synthesis, vitamin K
deficiency, isolated reduction of one of these factors, or
increased consumption, could raise PT.
Therefore, impairment of liver synthesis could
contribute to the increased PT verified .in our patients,
favored by simuItaneous PK and PA decrease. An
increased turnover, due to acti vation of blood coagulation
could also have contributed to this finding.
Tbere .was no correlation between PK and PT,
suggesting the kallikrein-kinin system does not play an
important role in this alteration.
In some patients (cases 1, 15 and 19) activation of
the blood coagulation intrinsic pathway by kallikrein is
suggested by simultaneous PK and factor XII decrease.
Further investigations are needed to clarify the
contact system in ANLL. Determination of kallikrein-C 1-
INH complexes or activity and antigen leveIs of PK and
C1-INH should be employed to elucidate these points.
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